1.56

13.04% 0.18

After Hours: 1.56

Alx Oncology Holdings Inc (ALXO)

Overview News Price History Option Chain Financials Discussions Forecast

Alx Oncology Holdings Inc stock is traded at $1.56, with a volume of 739.22K. It is up +13.04% in the last 24 hours and up +4.00% over the past month. ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.

Previous Close:

$1.38

Open:

$1.39

24h Volume:

739.22K

Relative Volume:

0.81

Market Cap:

$74.82M

Revenue:

Net Income/Loss:

$-151.16M

P/E Ratio:

-0.5253

EPS:

-2.97

Net Cash Flow:

$-130.08M

1W Performance:

+22.83%

1M Performance:

+4.00%

6M Performance:

+256.65%

1Y Performance:

+20.93%

1-Day Range:

$1.36

$1.65

1-Week Range:

$1.1781

$1.65

52-Week Range:

$0.404

$2.27

Alx Oncology Holdings Inc Stock (ALXO) Company Profile

Name

Alx Oncology Holdings Inc

Sector

Healthcare (1140)

Industry

Biotechnology (634)

Phone

650-466-7125

Address

323 ALLERTON AVENUE, SOUTH SAN FRANCISCO

Employee

Twitter

Next Earnings Date

2024-11-11

Latest SEC Filings

ALXO's Discussions on Twitter

Compare ALXO with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ALXO Alx Oncology Holdings Inc	1.56	74.82M	0	-151.16M	-130.08M	-2.97
ARGX Argen X Se Adr	929.61	55.90B	3.06B	1.28B	447.35M	19.67
VRTX Vertex Pharmaceuticals Inc	434.02	110.91B	11.74B	3.68B	3.34B	14.19
INSM Insmed Inc	197.40	41.21B	447.02M	-1.18B	-906.14M	-6.1812
ONC Beone Medicines Ltd Adr	376.63	40.48B	4.98B	69.59M	525.67M	0.5197
REGN Regeneron Pharmaceuticals Inc	704.31	72.89B	14.25B	4.58B	3.88B	41.77

Alx Oncology Holdings Inc Stock (ALXO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-13-25	Initiated	Jefferies	Buy
Mar-06-25	Upgrade	Jefferies	Hold → Buy
Dec-19-24	Downgrade	Jefferies	Buy → Hold
Mar-08-24	Downgrade	Stifel	Buy → Hold
Dec-08-23	Upgrade	Jefferies	Hold → Buy
Dec-22-21	Downgrade	Jefferies	Buy → Hold
Sep-30-21	Initiated	Stifel	Buy
May-05-21	Resumed	Credit Suisse	Outperform
Apr-26-21	Resumed	Credit Suisse	Outperform
Apr-06-21	Initiated	UBS	Buy
Feb-10-21	Initiated	H.C. Wainwright	Buy
Aug-11-20	Initiated	Cantor Fitzgerald	Overweight
Aug-11-20	Initiated	Credit Suisse	Outperform
Aug-11-20	Initiated	Jefferies	Buy
Aug-11-20	Initiated	Piper Sandler	Overweight

View All

Alx Oncology Holdings Inc Stock (ALXO) Latest News

07:07 AM

Statistical indicators supporting ALX Oncology Holdings Inc.’s strengthQuarterly Growth Report & Consistent Profit Trading Strategies - newser.com

07:07 AM

Nov 16, 2025

Will ALX Oncology Holdings Inc. outperform the marketJuly 2025 Catalysts & Community Verified Swing Trade Signals - newser.com

Nov 16, 2025

Is ALX Oncology Holdings Inc. stock attractive for hedge fundsMarket Performance Report & Daily Risk Controlled Trade Plans - newser.com

Nov 16, 2025

Applying Wyckoff theory to ALX Oncology Holdings Inc. stock2025 Institutional Moves & Safe Swing Trade Setup Alerts - newser.com

Nov 16, 2025

Will ALX Oncology Holdings Inc. continue its uptrendPortfolio Risk Summary & Low Drawdown Momentum Trade Ideas - newser.com

Nov 16, 2025

Nov 15, 2025

Can ALX Oncology Holdings Inc. hit a new high this monthTrade Analysis Report & Fast Momentum Entry Tips - newser.com

Nov 15, 2025

Nov 14, 2025

Can ALX Oncology Holdings Inc. stock attract ESG capital inflowsShort Setup & Weekly Chart Analysis and Guides - newser.com

Nov 14, 2025

Nov 13, 2025

Key metrics from ALX Oncology Holdings Inc.’s quarterly data2025 Year in Review & Real-Time Volume Analysis Alerts - newser.com

Nov 13, 2025

Jefferies initiates coverage on ALX Oncology stock with Buy rating By Investing.com - Investing.com Canada

Nov 13, 2025

Nov 12, 2025

Building trade automation scripts for ALX Oncology Holdings Inc.Weekly Trade Recap & Reliable Breakout Stock Forecasts - newser.com

Nov 12, 2025

Analyzing recovery setups for ALX Oncology Holdings Inc. investors2025 Momentum Check & Consistent Profit Trading Strategies - newser.com

Nov 12, 2025

Nov 11, 2025

ALX Oncology Holdings Inc. 2025 Q3ResultsEarnings Call Presentation (NASDAQ:ALXO) 2025-11-11 - Seeking Alpha

Nov 11, 2025

Will ALX Oncology Holdings Inc. stock reach Wall Street targets2025 Support & Resistance & Low Risk Entry Point Guides - newser.com

Nov 11, 2025

Nov 10, 2025

Analysts Offer Insights on Healthcare Companies: Veeva Systems (VEEV), ALX Oncology Holdings (ALXO) and Cencora (COR) - The Globe and Mail

Nov 10, 2025

ALX Oncology anticipates $2B–$4B HER2/CD47 breast cancer market opportunity while advancing biomarker-driven strategies - MSN

Nov 10, 2025